Nanomedicine for improvement of dendritic cell-based cancer immunotherapy

Hashemi, V and Farhadi, S and Ghasemi Chaleshtari, M and Seashore-Ludlow, B and Masjedi, A and Hojjat-Farsangi, M and Namdar, A and Ajjoolabady, A and Mohammadi, H and Ghalamfarsa, G and Jadidi-Niaragh, F (2020) Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. International Immunopharmacology, 83. ISSN 15675769

Full text not available from this repository.
Official URL:


Dendritic cell (DC)-based cancer immunotherapy has shown impressive outcomes, including the development of the first FDA-approved anti-cancer vaccine. However, the clinical application of DC-based cancer immunotherapy is associated with various challenges. Promising novel tools for the administration of cancer vaccines has emerged from recent developments in nanoscale biomaterials. One current strategy to enhance targeted drug delivery, while minimizing drug-related toxicities, is the use of nanoparticles (NPs). These can be utilized for antigen delivery into DCs, which have been shown to provide potent T cell-stimulating effects. Therefore, NP delivery represents one promising approach for creating an effective and stable immune response without toxic side effects. The current review surveys cancer immunotherapy with particular attention toward NP-based delivery methods that target DCs.

Item Type: Article
Uncontrolled Keywords: Cancer immunotherapies Dendritic cell vaccine Nanomedicine
Subjects: QW Microbiology and Immunology
Divisions: Research Center > Persian Gulf Marine Biotechnology Research Center
Depositing User: خدیجه شبانکاره
Date Deposited: 22 Dec 2020 09:29
Last Modified: 22 Dec 2020 09:29

Actions (login required)

View Item View Item